Gadolinium

Overview

Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance	2023/01/20	NCT05692635	Phase 2	Recruiting	Wake Forest University Health Sciences
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer	2021/03/22	NCT04809584	N/A	APPROVED_FOR_MARKETING	Stanford University
CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma	2021/01/27	NCT04727242	Phase 2	Recruiting	Kristen Ganjoo
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma	2020/07/16	NCT04474353	Phase 1	Active, not recruiting	Stanford University
Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) Vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients with Cirrhosis	2020/02/28	NCT04288323	Phase 4	Recruiting	University of California, San Diego
Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military	2019/08/15	NCT04058132	Phase 2	Terminated	Uniformed Services University of the Health Sciences
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System	2017/09/01	NCT03270059	Phase 2	Recruiting	OHSU Knight Cancer Institute
Chronic Convection Enhanced Delivery of Topotecan	2017/05/16	NCT03154996	Phase 1	Completed	Jeffrey N. Bruce
Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)	2017/03/01	NCT03067467	N/A	Recruiting	University of Texas Southwestern Medical Center
Diffusion MRI in Heart Failure	2016/11/25	NCT02973633	Early Phase 1	UNKNOWN	Massachusetts General Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Metox	Deseret Biologicals, Inc.	43742-1312	ORAL	12 [hp_X] in 1 mL	5/27/2025
MetDetox	Dr. Donna Restivo DC	62185-0062	ORAL	12 [hp_X] in 1 mL	5/23/2025

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Bayer Submits Low-Dose MRI Contrast Agent Gadoquatrane for Global Regulatory Approval

a month ago

Bayer has submitted marketing authorization applications for gadoquatrane, an investigational MRI contrast agent that delivers 60% lower gadolinium dosing compared to standard agents while maintaining diagnostic efficacy.

Orviglance Shows Superior Liver Lesion Detection in Phase II Study Published in Investigative Radiology

3 months ago

Ascelia Pharma's orphan drug candidate Orviglance demonstrated statistically significant superior visualization of liver lesions compared to unenhanced MRI in a Phase II study of colorectal cancer metastases patients.

Bayer's Gadoquatrane Achieves Positive Phase III Results with Reduced Gadolinium Dose

6 months ago

Bayer's investigational MRI contrast agent, gadoquatrane, met primary and secondary endpoints in Phase III QUANTI studies.

GE HealthCare's Novel Manganese-Based MRI Contrast Agent Shows Promise in Phase I Trial

9 months ago

GE HealthCare's first-in-human study of a macrocyclic manganese-based MRI contrast agent demonstrates it was well tolerated with no serious adverse events.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access